TEVIMBRA®
(tislelizumab)
BEIGENE
HK Reg. No. HK-68407 (14 Oct, 2024)
Composition:3
• Available as solution for injection (100 mg/10 mL clear to slightly opalescent, colorless to slightly yellow solution in a single dose vial)
Indication:3
• Indicated, as a single agent, for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor
References
1. EMA. Mounjaro Summary of Product Characteristics. 25 October 2024. Available from: https://www.ema.europa.eu/en/documents/product-information/mounjaro-epar-product-information_en.pdf [Accessed 6 November 2024].
2. FDA. ALTUVIIIO® Highlights of Prescribing Information. May 2024. Available from: https://www.fda.gov/media/165594/download. [Accessed 6 November 2024].
3. FDA. TEVIMBRA® Highlights of Prescribing Information. March 2024. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761232Orig1s000lbl.pdf [Accessed 7 November 2024].
